By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Waters today reported fourth-quarter 2011 results that beat analyst estimates on the top and bottom line.

For the period ended Dec. 31, the firm posted net sales of $521.4 million, up 8 percent from $483.6 million a year ago and surpassing Wall Street expectations of $516.9 million.

Organically, sales were up 8 percent for the quarter, President and CEO Douglas Berthiaum said during a conference call following the release of Waters' results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.